A Phase 2a, Open-Label, Multi-Center Study to Assess the Efficacy and Safety of Marrow Infiltrating Lymphocytes Non- Small Cell Lung Cancer (MILs - NSCLC) Alone or in Combination with Nivolumab in Subjects with Locally Advanced and Unresectable or Metastatic NSCLC Previously Treated with Anti-PD-1
Categories (click each to see list of all clinical trials associated with that category): Lung/Thoracic
Current Status: Open to accrual
Phase: II
Principal Investigator: Buddharaju, Laxmi Narayana
Contact Information:
Desiree Hanna
desiree.hanna@unmc.edu
Eligibility: https://clinicaltrials.gov/ct2/show/NCT04069936?cond=NCT04069936&draw=2&rank=1#eligibility
Summary